MedTrace Logo

Comparing the Effectiveness Between Ritonavir Boosted Atazanavir and Efavirenz for the First HIV Treatment

NCT00280969 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 71

Last updated 2015-03-30

No results posted yet for this study

Summary

A selection study in treatment naive HIV patients to compare the virologic success rate of once daily antiretroviral treatment regimens at the 48th week with Epzicom(lamivudine and abacavir) plus efavirenz and Epzicom plus ritonavir boosted atazanavir. The superior regimen will be hired to the comparative study to the current first line regimen (tenofovir plus lamivudine plus efavirenz)

Conditions

  • HIV Infection

Interventions

DRUG

atazanavir arm

Patients are treated with ritonavir 100mg boosted atazanavir 300mg along with Epzicom.

DRUG

efavirenz

Patients are treated with efavirenz 300mg along with Epzicom.

Sponsors & Collaborators

  • Ministry of Health, Labour and Welfare, Japan

    collaborator OTHER_GOV

  • International Medical Center of Japan

    lead OTHER_GOV

Principal Investigators

  • Shinichi Oka, M.D., phD. · International Medical Center of Japan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2009-09-30
Completion
2009-09-30

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00280969 on ClinicalTrials.gov